Mental Health Clinics in Weehawken, NJ Accepting Medicare
5 Mental Health Clinics found. Showing 1 - 5
 Array Psychological Assessments Clinical Neuropsychologist Medicare: Not Enrolled in Medicare Practice Location: 1300 Avenue At Port Imperial Apt 443, Weehawken, NJ 07086 Phone: 914-297-9187 |
Dr Rena Miller Psychological Services Llc Counselor Medicare: Not Enrolled in Medicare Practice Location: 941 Boulevard E, Weehawken, NJ 07086 Phone: 347-948-3362 |
Lighthouse Therapy Clinic - Adult Mental Health Medicare: Not Enrolled in Medicare Practice Location: 6 Fulton St Apt 2, Weehawken, NJ 07086 Phone: 551-327-9077 |
Lion House Recovery Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 65 46th St Apt 2, Weehawken, NJ 07086 Phone: 310-463-1782 |
Steps Of Care Aba Services Llc Behavioral Analyst Medicare: Not Enrolled in Medicare Practice Location: 708 Boulevard E Apt C3, Weehawken, NJ 07086 Phone: 786-317-8590 |
News Archive
Can-Fite BioPharma to commence Glaucoma Phase II clinical study in Israel
Can-Fite BioPharma, a biotechnology company traded on the Tel Aviv Stock Exchange, announced on December 13 the initiation of the regulatory process for a Glaucoma Phase II clinical study in Israel. Leading Medical Centers in Israel will enroll 44 patients with Ocular Hypertension or Glaucoma for the first segment of the trial, who will be treated for 16 weeks with CF101 or placebo.
Non-invasive imaging technique measures specific brain chemical changes
Alzheimer's disease (AD) is a major neurodegenerative disorder that affects millions of people worldwide. New and accurate techniques for early diagnosis are critical. Pravat K. Mandal, PhD, and his colleagues have developed a completely non-invasive brain imaging technique to measure specific brain chemical changes. This provides a signature of the early stages of AD from the hippocampal region of the brain.
NHLBI selects NuGEN to provide automated reagent solutions for expression profiling
NuGEN Technologies, the provider of innovative RNA and DNA amplification and sample preparation technologies for genomic analysis, today announced it has been selected by the National Heart, Lung, and Blood Institute (NHLBI) to provide automated reagent solutions for expression profiling of approximately 6,000 blood samples from the Framingham Heart Study.
Akebia completes AKB-6548 Phase 2 study for anemia in CKD patients
Akebia Therapeutics, Inc., a pharmaceutical discovery and development company focused on anemia and vascular disorders, today announced that it has successfully completed a randomized, double-blinded, placebo-controlled Phase 2 dose-ranging study of AKB-6548 in patients with stage 3 and 4 chronic kidney disease (CKD).
New study details weight loss patterns of breastfed newborns
Using weights obtained from over 100,000 Northern California babies, a new study is the first to detail the weight loss patterns of exclusively breastfed newborns. The results show that some breastfed babies lose weight faster and for a longer period than was previously recognized.
› Verified 4 days ago